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ABSTRACT  
A simple, precise and accurate RP-HPLC method was developed and validated for the estimation of gemifloxacin in the tablet dosage form. The 
separation was achieved on a reversed-phase C-18 column (250 x 4.6 mm i.d., 5 µm) using a mobile phase consisting of acetonitrile/acetate 
buffer of pH 4.5 (70:30 v/v) at a flow rate of 1.0 ml/min and a detection wavelength of 244 nm. The separation was carried out on an isocratic 
mode at room temperature. The method was validated as per ICH guidelines for linearity, accuracy, precision, robustness, LOD, LOQ and 
specificity. The developed method showed good linearity over the concentration range of 50-150 µg/ml (r2=0.995). The average percentage 
recovery was 99.77%. The LOD and LOQ were 12.678 µg/ml and 14.261 µg/ml, respectively. Based upon validation studies, the developed 
method can be successfully applied for the routine analysis of gemifloxacin in bulk drugs as well as pharmaceutical dosage forms. 
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INTRODUCTION 
Gemifloxacin is an oral broad-spectrum quinolone 
antibacterial agent used in the treatment of chronic 
bronchitis and mild-to-moderate pneumonia. Chemically, 
gemifloxacin is 7-[(4Z)-3-(aminomethyl)-4-(methoxyimino) 
pyrrolidin-1-yl]-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-
1,8-naphthyridine-3-carboxylic acid (Figure 1)1,2. It is an 
important antibacterial compound fall under the class of 
fluoroquinolone antibiotics and is available as the mesylate 
salt in the sesquihydrate form. The bactericidal action of 
gemifloxacin results from inhibition of the enzymes 
topoisomerase II (DNA gyrase) and topoisomerase IV, which 
are required for bacterial DNA replication, transcription, 
repair, and recombination3,4. It occurs as white to off-white 
crystalline powder usually soluble in methanol, dimethyl 
sulfoxide, and water5. In this paper, a simple and specific RP-
HPLC method was developed and validated (as per ICH 
guidelines) for the estimation gemifloxacin in the tablet 
dosage form. 
 
 
 
Figure 1: Chemical structure of gemifloxacin 
MATERIALS AND METHODS  
Chemicals  
Acetonitrile, methanol and water (Merck, Rankem) used in 
the study were of HPLC grade. All other chemicals were of 
analytical grade. The gemifloxacin bulk drug was obtained as 
gift sample from Chandra Laboratories, Hyderabad. The 
tablet dosage form of gemifloxain was procured from the 
local medical store.  
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Apparatus and Instruments  
UV-Visible spectrophotometer (Analytical Technologies Ltd.), 
HPLC (Waters), ultra sonicator (Citizen, Digital Ultrasonic 
Cleaner), pH meter (Elico) and electronic weighing balance 
(Shimadzu) were used for analytical studies. 
Chromatographic Parameters 
Chromatographic analysis was performed on a RP-HPLC 
equipped with a pump, manual sampler and a UV detector. 
The chromatographic column was a Develosil Rp Aqueous-
AR-5 C18 column (250 mm × 4.6 mm i.d., 5 µm). The column 
temperature was maintained at 25 oC. The mobile phase 
consisted of acetonitrile/acetate buffer (pH 4.5)/ (70:30% 
v/v). The separation was achieved on an isocratic mode at 
ambient temperature. The flow rate was 1.0 ml/min and the 
injection volume was 20 µl. The run time was 5.0 min. The 
wavelength of UV detection was set at 244 nm.  
Preparation of Solutions6,7 
About 100 mg of  gemifloxacin weighed into a 100 ml 
volumetric flask, added to this 25 ml of mobile phase, 
sonicated for 20 minutes and the volume was made up to the 
mark with the mobile phase to obtain a concentration of 
1000 µg/ml.  Further dilutions were made with the same 
solvent to prepare a series of standard solutions in the 
concentration range of 50-150 µg/ml of gemifloxacin. 
Twenty tablets were accurately weighed and finely 
powdered. Powder equivalent to 100 mg of gemifloxacin was 
accurately weighed, transferred into a 100 ml volumetric 
flask and dissolved in mobile phase to obtain a sample stock 
solution of 1000 μg/ml.  The solution was sonicated for 20 
minutes and filtered through Whatman filter paper. Using 
the stock solution, final sample solutions were prepared in 
the concentration range of 50-150 μg/ml using the same 
solvent.  
RESULTS AND DISCUSSION 
Preliminary studies involved several trial runs using C18 
reversed-phase columns, various mobile phase compositions 
and different flow rates for the separation of gemifloxacin 
with optimum chromatographic parameters (resolution, 
symmetry, tailing factor etc.). A C18 column (250 mm × 4.6 
mm i.d., 5µm.) stationary phase with a mobile phase 
consisting of acetonitrile/ acetate buffer (pH 4.5) (70:30 v/v) 
at a flow rate of 1.0 ml/min and a detection wavelength of 
244 nm afforded the best separation with well-resolved and 
sharp peak. The summary of optimum chromatographic 
conditions is depicted in Table 1. 
 
Table 1: Optimum chromatographic conditions 
Chromatographic parameter Condition 
Mobile phase  Acetonitrile/ammonium acetate buffer (pH 4.5) (70:30) 
Column  Develosil Rp Aqueous-AR-5 (250 x 4.6 mm, 5 µm) 
Flow rate  1 ml/min 
Column temperature  Room temperature (20-25 oC) 
Sample temperature Room temperature (20-25 oC) 
Wavelength  244 nm 
Injection volume 20 µl 
Run time 5 min. 
Retention time 3.084 min.  
 
 
After method development, validation of the developed 
method was performed in terms of the following 
parameters: linearity, accuracy, precision, robustness, limit 
of detection (LOD), limit of quantitation (LOQ) and 
specificity8-12.  
Linearity 
The linearity of the method was evaluated by analyzing six 
(n=6) calibration standards of gemifloxacin for a 
concentration range of 50-150 µg/ml at 244 nm. The plot of 
peak area versus concentration was found linear in the 
range of in the range of 50-150 µg/ml (Figure 2). The 
regression equation was obtained as follows: y =19546x + 
49926 (r2=0.9953), where y = peak area, x = concentration of 
solution, r = the square of determined correlation coefficient. 
From results it is clear that the developed method is linear 
over the specified range. 
 
Figure 2: Calibration curve of gemifloxacin  
 
 
 
y = 19546x + 49926 
r² = 0.9953 
0
500000
1000000
1500000
2000000
2500000
3000000
3500000
0 20 40 60 80 100 120 140 160
A
re
a
 
Conc. (µg/ml ) 
Rudrapal et al                                                                                                                    Journal of Drug Delivery & Therapeutics. 2020; 10(4):97-101 
ISSN: 2250-1177                                                                                        [99]                                                                                    CODEN (USA): JDDTAO 
Accuracy 
The accuracy of the method was determined by percentage 
recovery assay. A known amount of each standard powder 
(with the same proportion as in the drug formulation) was 
added to blank sample composed of all the excipients 
equivalent to the ratio of the tablet formulation, which was 
then mixed, extracted and subsequently diluted to obtain 
three different levels of concentration (50, 100 and 150 
µg/ml). The study was performed three times (n=3) at 50%, 
100% and 150% concentration. The method was found to be 
accurate with % recovery of 99.77%. The RSD values of peak 
areas were found to be less than 1% at each level.  
Precision 
The system precision and method precision were 
determined by analysing sample solution of gemifloxacin in 
six replications (n=6). The % RSD values for system and 
method precision studies were found to be within the 
acceptance criteria of less than 2.0%. Results indicate good 
precision of the developed method.  
Robustness 
The robustness of the methods was investigated by 
analyzing six replicates (n=6) of sample solution by 
deliberate variations in the UV spectrometric measurements 
such as temperature and chromatographic conditions such 
as flow rate. Results of robustness studies indicate that the 
developed method is practically robust. The % RSD values of 
the method determined under robustness conditions were 
less than 2.0%.  
LOD and LOQ  
The LOD and LOQ for the developed RP-HPLC method were 
found to be 12.678 µg/ml and 14.261 µg/ml, respectively. 
Results of LOD and LOQ imply that the developed method is 
sensitive for the precise determination of gemifloxacin in the 
marketed formulation.   
Specificity 
The standard and sample solutions (100 μg/ml) of 
gemifloxacin were injected and the chromatograms were 
recorded. No additional peaks due to impurities or other 
related substances were observed adjacent to the peak of 
interest in the chromatogram of gemifloxacin. The analyte 
peak for gemifloxacin was obtained with the retention time 
of 3.084 min. Result of specificity studies demonstrates that 
the RP-HPLC method is highly specific. Chromatograms also 
indicate that the method is free from interferences due to 
excipients and/or related components (Figure 3). 
  
 
(a)                                                                                                  (b) 
Figure 3: Chromatogram of standard (a) and sample (b) 
 
Assay 
Weighed a quantity of powder equivalent to 100 mg of 
gemifloxacin in 100 ml volumetric flask and the volume was 
made up to the mark with mobile phase. From this stock 
solution, a sample solution of 100 μg/ml was prepared and 
used for the estimation of gemifloxacin. A chromatogram 
was recorded (Figure 4). The amount of gemifloxaxin in the 
tablet dosage form was calculated from the peak area of 
recorded chromatogram. The amount estimated was in good 
agreement with the label claimed. The assay of gemifloxacin 
(% gemifloxacin) in the tablet dosage form was found to be 
99.90%. The percentage purity of gemifloxacin was found to 
be within the standard limit i.e., 98-102 %. 
System suitability 
System suitability was determined by injecting six replicate 
injections of the standard solution (100 µg/ml) of 
gemifloxacin13-15. Results of system suitability parameters 
depicted in Table 2 are within acceptable limit. 
 
 
Figure 4: Assay chromatogram of gemifloxacin 
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Table 2: Results of validation parameters 
Parameter Result 
Wave length of detection (λmax, nm)  244 
Linearity  Range (μg/ml) 50-150 
Slope 19546 
Intercept 49926 
Coefficient of correlation 0.9953 
Accuracy   % Recovery* %RSD (<2.0) 
50% 99.13 Average: 
99.77 
 
0.12-0.13 100% 100.02 
150% 100.18 
Precision Peak area** %RSD (<2.0) 
System precision 1964334.83 0.13  
Method precision 1963997.00 0.12 
Robustness**  Peak area** %RSD (<2.0) 
Wavelength (nm)  
0.13 242 2101531 
246 2101435 
Flow rate (ml/min)  
0.12 0.8 218891 
1.2 2182155 
LOD (µg/ml) 12.678 0.12 
LOQ (µg/ml) 14.261 0.12 
System suitability Retention time (min.) 3.084  
Peak area 1962155  
Theoretical plates 6193 
Tailing factor 1.266 
Assay*  Amount (mg) % Estimated  
Label claim  320.0 99.90 
Amount found 319.8 
            *mean of three determinations (n=3)                          **mean of six replicate observations (n=6) 
 
 
CONCLUSION 
In this paper, a RP-HPLC method was developed and 
validated for the estimation of gemifloxacin in the marketed 
tablet dosage form. The developed method was successful 
for the estimation of gemifloxacin in the tablet formulation. 
The proposed method is claimed to be simple, accurate and 
precise. The developed method is also reported to be highly 
valid, specific and reliable. Based upon validation studies, 
the proposed method can be applied for the routine analysis 
of gemifloxacin in bulk drugs as well as pharmaceutical 
dosage forms. 
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